nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Induration—Bleomycin—lymphatic system cancer	0.036	0.036	CcSEcCtD
Oritavancin—Extravasation—Teniposide—lymphatic system cancer	0.0286	0.0286	CcSEcCtD
Oritavancin—Hyperuricaemia—Fludarabine—lymphatic system cancer	0.0236	0.0236	CcSEcCtD
Oritavancin—Blood uric acid increased—Fludarabine—lymphatic system cancer	0.0223	0.0223	CcSEcCtD
Oritavancin—Allergic cutaneous angiitis—Methotrexate—lymphatic system cancer	0.0204	0.0204	CcSEcCtD
Oritavancin—Extravasation—Bleomycin—lymphatic system cancer	0.0184	0.0184	CcSEcCtD
Oritavancin—Abscess—Carmustine—lymphatic system cancer	0.0177	0.0177	CcSEcCtD
Oritavancin—Extravasation—Carmustine—lymphatic system cancer	0.0161	0.0161	CcSEcCtD
Oritavancin—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0161	0.0161	CcSEcCtD
Oritavancin—Wheezing—Bleomycin—lymphatic system cancer	0.0156	0.0156	CcSEcCtD
Oritavancin—Bronchospasm—Teniposide—lymphatic system cancer	0.0154	0.0154	CcSEcCtD
Oritavancin—Extravasation—Vincristine—lymphatic system cancer	0.0154	0.0154	CcSEcCtD
Oritavancin—Extravasation—Mitoxantrone—lymphatic system cancer	0.015	0.015	CcSEcCtD
Oritavancin—Hyperuricaemia—Vincristine—lymphatic system cancer	0.0144	0.0144	CcSEcCtD
Oritavancin—Hyperuricaemia—Mitoxantrone—lymphatic system cancer	0.0141	0.0141	CcSEcCtD
Oritavancin—Blood bilirubin increased—Mitoxantrone—lymphatic system cancer	0.0138	0.0138	CcSEcCtD
Oritavancin—Blood uric acid increased—Vincristine—lymphatic system cancer	0.0136	0.0136	CcSEcCtD
Oritavancin—Blood uric acid increased—Mitoxantrone—lymphatic system cancer	0.0133	0.0133	CcSEcCtD
Oritavancin—Leukocytoclastic vasculitis—Methotrexate—lymphatic system cancer	0.0133	0.0133	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.0125	0.0125	CcSEcCtD
Oritavancin—Infection—Mechlorethamine—lymphatic system cancer	0.012	0.012	CcSEcCtD
Oritavancin—Skin disorder—Mechlorethamine—lymphatic system cancer	0.0117	0.0117	CcSEcCtD
Oritavancin—Erythema multiforme—Fludarabine—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Oritavancin—Anaemia—Teniposide—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Oritavancin—Bronchospasm—Bleomycin—lymphatic system cancer	0.00992	0.00992	CcSEcCtD
Oritavancin—Malnutrition—Fludarabine—lymphatic system cancer	0.00959	0.00959	CcSEcCtD
Oritavancin—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0089	0.0089	CcSEcCtD
Oritavancin—Anaemia—Fludarabine—lymphatic system cancer	0.00886	0.00886	CcSEcCtD
Oritavancin—Infection—Teniposide—lymphatic system cancer	0.00884	0.00884	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00876	0.00876	CcSEcCtD
Oritavancin—Tachycardia—Teniposide—lymphatic system cancer	0.00869	0.00869	CcSEcCtD
Oritavancin—Pruritus—Mechlorethamine—lymphatic system cancer	0.00854	0.00854	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00853	0.00853	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00835	0.00835	CcSEcCtD
Oritavancin—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00826	0.00826	CcSEcCtD
Oritavancin—Abscess—Methotrexate—lymphatic system cancer	0.00822	0.00822	CcSEcCtD
Oritavancin—Myalgia—Fludarabine—lymphatic system cancer	0.00816	0.00816	CcSEcCtD
Oritavancin—Infection—Fludarabine—lymphatic system cancer	0.00777	0.00777	CcSEcCtD
Oritavancin—Vomiting—Mechlorethamine—lymphatic system cancer	0.00768	0.00768	CcSEcCtD
Oritavancin—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00767	0.00767	CcSEcCtD
Oritavancin—Rash—Mechlorethamine—lymphatic system cancer	0.00761	0.00761	CcSEcCtD
Oritavancin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00761	0.00761	CcSEcCtD
Oritavancin—Extravasation—Methotrexate—lymphatic system cancer	0.00745	0.00745	CcSEcCtD
Oritavancin—Nausea—Mechlorethamine—lymphatic system cancer	0.00717	0.00717	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00713	0.00713	CcSEcCtD
Oritavancin—Urticaria—Teniposide—lymphatic system cancer	0.00707	0.00707	CcSEcCtD
Oritavancin—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.00701	0.00701	CcSEcCtD
Oritavancin—Oedema peripheral—Carmustine—lymphatic system cancer	0.00694	0.00694	CcSEcCtD
Oritavancin—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00693	0.00693	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00675	0.00675	CcSEcCtD
Oritavancin—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.00662	0.00662	CcSEcCtD
Oritavancin—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00661	0.00661	CcSEcCtD
Oritavancin—Hypersensitivity—Teniposide—lymphatic system cancer	0.00656	0.00656	CcSEcCtD
Oritavancin—Anaemia—Bleomycin—lymphatic system cancer	0.0065	0.0065	CcSEcCtD
Oritavancin—Pruritus—Teniposide—lymphatic system cancer	0.0063	0.0063	CcSEcCtD
Oritavancin—Cardiac disorder—Vincristine—lymphatic system cancer	0.00624	0.00624	CcSEcCtD
Oritavancin—Malnutrition—Carmustine—lymphatic system cancer	0.00613	0.00613	CcSEcCtD
Oritavancin—Diarrhoea—Teniposide—lymphatic system cancer	0.00609	0.00609	CcSEcCtD
Oritavancin—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00606	0.00606	CcSEcCtD
Oritavancin—Myalgia—Bleomycin—lymphatic system cancer	0.00598	0.00598	CcSEcCtD
Oritavancin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00576	0.00576	CcSEcCtD
Oritavancin—Infection—Bleomycin—lymphatic system cancer	0.0057	0.0057	CcSEcCtD
Oritavancin—Anaemia—Carmustine—lymphatic system cancer	0.00567	0.00567	CcSEcCtD
Oritavancin—Vomiting—Teniposide—lymphatic system cancer	0.00566	0.00566	CcSEcCtD
Oritavancin—Rash—Teniposide—lymphatic system cancer	0.00561	0.00561	CcSEcCtD
Oritavancin—Dermatitis—Teniposide—lymphatic system cancer	0.00561	0.00561	CcSEcCtD
Oritavancin—Headache—Teniposide—lymphatic system cancer	0.00558	0.00558	CcSEcCtD
Oritavancin—Pruritus—Fludarabine—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Oritavancin—Anaemia—Vincristine—lymphatic system cancer	0.00541	0.00541	CcSEcCtD
Oritavancin—Diarrhoea—Fludarabine—lymphatic system cancer	0.00535	0.00535	CcSEcCtD
Oritavancin—Nausea—Teniposide—lymphatic system cancer	0.00529	0.00529	CcSEcCtD
Oritavancin—Anaemia—Mitoxantrone—lymphatic system cancer	0.00527	0.00527	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00523	0.00523	CcSEcCtD
Oritavancin—Myalgia—Carmustine—lymphatic system cancer	0.00522	0.00522	CcSEcCtD
Oritavancin—Myalgia—Vincristine—lymphatic system cancer	0.00499	0.00499	CcSEcCtD
Oritavancin—Infection—Carmustine—lymphatic system cancer	0.00497	0.00497	CcSEcCtD
Oritavancin—Vomiting—Fludarabine—lymphatic system cancer	0.00497	0.00497	CcSEcCtD
Oritavancin—Rash—Fludarabine—lymphatic system cancer	0.00493	0.00493	CcSEcCtD
Oritavancin—Dermatitis—Fludarabine—lymphatic system cancer	0.00493	0.00493	CcSEcCtD
Oritavancin—Headache—Fludarabine—lymphatic system cancer	0.0049	0.0049	CcSEcCtD
Oritavancin—Tachycardia—Carmustine—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Oritavancin—Myalgia—Mitoxantrone—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Oritavancin—Infection—Vincristine—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Oritavancin—Nervous system disorder—Vincristine—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Oritavancin—Nausea—Fludarabine—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Oritavancin—Infection—Mitoxantrone—lymphatic system cancer	0.00462	0.00462	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Oritavancin—Urticaria—Bleomycin—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Oritavancin—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00454	0.00454	CcSEcCtD
Oritavancin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00432	0.00432	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Oritavancin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Oritavancin—Pruritus—Bleomycin—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Oritavancin—Eosinophilia—Methotrexate—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Oritavancin—Urticaria—Mitoxantrone—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Oritavancin—Hypersensitivity—Carmustine—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Oritavancin—Vomiting—Bleomycin—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Oritavancin—Infestation NOS—Methotrexate—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Oritavancin—Infestation—Methotrexate—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Oritavancin—Rash—Bleomycin—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Oritavancin—Dermatitis—Bleomycin—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Oritavancin—Hypersensitivity—Vincristine—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Oritavancin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Oritavancin—Diarrhoea—Carmustine—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Oritavancin—Nausea—Bleomycin—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Oritavancin—Dizziness—Carmustine—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Oritavancin—Diarrhoea—Vincristine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Oritavancin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Oritavancin—Vomiting—Carmustine—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Oritavancin—Dizziness—Vincristine—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Oritavancin—Rash—Carmustine—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Oritavancin—Dermatitis—Carmustine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Oritavancin—Headache—Carmustine—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Oritavancin—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Oritavancin—Vomiting—Vincristine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Oritavancin—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Oritavancin—Rash—Vincristine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Oritavancin—Dermatitis—Vincristine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Oritavancin—Headache—Vincristine—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Oritavancin—Nausea—Carmustine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Oritavancin—Vomiting—Mitoxantrone—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Oritavancin—Immune system disorder—Methotrexate—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Oritavancin—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Oritavancin—Rash—Mitoxantrone—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Oritavancin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Oritavancin—Headache—Mitoxantrone—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Oritavancin—Malnutrition—Methotrexate—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Oritavancin—Nausea—Vincristine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Oritavancin—Nausea—Mitoxantrone—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Oritavancin—Anaemia—Methotrexate—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Oritavancin—Myalgia—Methotrexate—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Oritavancin—Infection—Methotrexate—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Oritavancin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Oritavancin—Skin disorder—Methotrexate—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.002	0.002	CcSEcCtD
Oritavancin—Urticaria—Methotrexate—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Oritavancin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Oritavancin—Pruritus—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Oritavancin—Diarrhoea—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Oritavancin—Dizziness—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Oritavancin—Vomiting—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Oritavancin—Rash—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Oritavancin—Dermatitis—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Oritavancin—Headache—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Oritavancin—Nausea—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
